Altmeyer A, Josset E, Denis JM, Gueulette J, Slabbert J, Mutter D, Noel G, Bischoff P (2012) The mTOR inhibitor RAD001 augments radiation-induced growth inhibition in a hepatocellular carcinoma cell line by increasing autophagy. Int J Oncol 41:1381–1386

Article  CAS  PubMed  Google Scholar 

Ariaans G, Jalving M, Vries EG, Jong S (2017) Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells. BMC Cancer 17:232

Article  PubMed  PubMed Central  Google Scholar 

Avniel-Polak S, Leibowitz G, Doviner V, Gross DJ, Grozinsky-Glasberg S (2018) Combining chloroquine with RAD001 inhibits tumor growth in a NEN mouse model. Endocr Relat Cancer 25:677–686

Article  CAS  PubMed  Google Scholar 

Bedke J, Gauler T, Grunwald V, Hegele A, Herrmann E, Hinz S, Janssen J, Schmitz S, Schostak M, Tesch H, Zastrow S, Miller K (2017) Systemic therapy in metastatic renal cell carcinoma. World J Urol 35:179–188

Article  CAS  PubMed  Google Scholar 

Bhat S (2010) Role of surgery in advanced/metastatic renal cell carcinoma. Indian J Urol 26:167–176

Article  PubMed  PubMed Central  Google Scholar 

Calderwood SK (2013) Tumor heterogeneity, clonal evolution, and therapy resistance: an opportunity for multitargeting therapy. Discov Med 15:188–194

PubMed  PubMed Central  Google Scholar 

Chao A, Lin CY, Wu RC, Lee YS, Lee LY, Tsai CL, Yang LY, Liu H, Chen SJ, Wang TH, Lai CH (2018) The combination of everolimus and terameprocol exerts synergistic antiproliferative effects in endometrial cancer: molecular role of insulin-like growth factor binding protein 2. J Mol Med (berl) 96:1251–1266

Article  CAS  PubMed  Google Scholar 

FDA approves drug combo for kidney cancer (2016) Cancer Discov 6:687–688

Google Scholar 

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386

Article  CAS  PubMed  Google Scholar 

Fisher R, Gore M, Larkin J (2013) Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol 23:38–45

Article  PubMed  Google Scholar 

Francois RA, Maeng K, Nawab A, Kaye FJ, Hochwald SN, Zajac-Kaye M (2015) Targeting focal adhesion kinase and resistance to mTOR inhibition in pancreatic neuroendocrine tumors. J Natl Cancer Inst 107(8):djv123. https://doi.org/10.1093/jnci/djv123

Gottlieb DJ, Hek K, Chen TH, Watson NF, Eiriksdottir G, Byrne EM, Cornelis M, Warby SC, Bandinelli S, Cherkas L, Evans DS, Grabe HJ, Lahti J, Li M, Lehtimäki T, Lumley T, Marciante KD, Pérusse L, Psaty BM, Robbins J, Tiemeier H (2015) Novel loci associated with usual sleep duration: the CHARGE Consortium Genome-Wide Association Study. Molecular psychiatry 20(10):1232–1239. https://doi.org/10.1038/mp.2014.133

Article  CAS  PubMed  Google Scholar 

Huang JJ, Li ZM, Huang Y, Tian Y, He XX, Xiao J, Lin TY (2012) Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs. Invest New Drugs 30:223–235

Article  CAS  PubMed  Google Scholar 

Hurvitz SA, Kalous O, Conklin D, Desai AJ, Dering J, Anderson L, O’Brien NA, Kolarova T, Finn RS, Linnartz R, Chen D, Slamon DJ (2015) In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. Breast Cancer Res Treat 149:669–680

Article  CAS  PubMed  Google Scholar 

Karam JA, Zhang XY, Tamboli P, Margulis V, Wang H, Abel EJ, Culp SH, Wood CG (2011) Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur Urol 59:619–628

Article  PubMed  Google Scholar 

Liu GY, Sabatini DM (2020) Author correction: mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol 21:246

Article  PubMed  Google Scholar 

Lui A, New J, Ogony J, Thomas S, Lewis-Wambi J (2016) Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells. BMC Cancer 16:487

Article  PubMed  PubMed Central  Google Scholar 

Saran U, Foti M, Dufour JF (2015) Cellular and molecular effects of the mTOR inhibitor everolimus. Clin Sci (lond) 129:895–914

Article  CAS  PubMed  Google Scholar 

Sharma R, Kadife E, Myers M, Kannourakis G, Prithviraj P, Ahmed N (2021) Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. J Exp Clin Cancer Res 40:186

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Yuan X, Li J, Liu Z, Li X, Wang Z, Wei L, Li Y, Wang X (2021) The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer. Frontiers in cell and developmental biology 9. https://doi.org/10.3389/fcell.2021.785796

Wedel S, Hudak L, Seibel JM, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA (2011) Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sci 88:418–424

Article  CAS  PubMed  Google Scholar 

Zhang Q, Zhang Y, Chen Y, Qian J, Zhang X, Yu K (2019) A novel mTORC1/2 inhibitor (MTI-31) inhibits tumor growth, epithelial-mesenchymal transition, metastases, and improves antitumor immunity in preclinical models of lung cancer. Clin Cancer Res 25:3630–3642

Article  CAS  PubMed  Google Scholar 

Zhang R, Chen X, Miao C, Chen Y, Li Y, Shen J, Yuan M, Chen M, Cheng J, Liu S, Sun Q, Wu J (2024) Tumor-associated macrophage-derived exosomal miR-513b-5p is a target of jianpi yangzheng decoction for inhibiting gastric cancer. Journal of ethnopharmacology 318(Pt B). https://doi.org/10.1016/j.jep.2023.117013